Analysis of chemotherapeutic response in ovarian cancers using publicly available high-throughput data

Cancer Research

Volumn 74, Issue 14, 2014, Pages 3902-3912

  Gonzalez Bosquet, Jesus ^a   Marchion, Douglas C ^b   Chon, HyeSook ^c   Lancaster, Johnathan M ^c   Chanock, Stephen ^d  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b Experimental Therapeutics Program   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRG1 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 14; PLATINUM COMPLEX; POLYCYSTIN 2; PROTEIN P53; TAXANE DERIVATIVE; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSCRIPTION FACTOR E2F1;

ADULT; APOPTOSIS; ARTICLE; C10ORF26 GENE; C13ORF33 GENE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CDK5RAP3 GENE; CELL CYCLE REGULATION; COL8A1 GENE; CONTROLLED STUDY; COPY NUMBER VARIATION; COPZ2 GENE; DNA METHYLATION; DNA REPAIR; DNA REPLICATION; DRUG RESPONSE; ERCC5 GENE; FEMALE; GCNT1 GENE; GENE; GENE CLUSTER; GENE IDENTIFICATION; GENE LOCATION; GENE MUTATION; GENETIC ASSOCIATION; GJB1 GENE; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMPACT GENE; INTRACELLULAR SIGNALING; KIAA1033 GENE; KRT72 GENE; LHFP GENE; MAJOR CLINICAL STUDY; MAPK14 GENE; MICROARRAY ANALYSIS; MUTATIONAL ANALYSIS; MYO5C GENE; NCRNA00184 GENE; ODZ1 GENE; OLFML3 GENE; OMD GENE; OVARY CARCINOMA; PARN GENE; PDGFD GENE; PILOT STUDY; PKD2 GENE; PRIORITY JOURNAL; PRPF40A GENE; RAB35 GENE; SMARCA4 GENE; SNRPA GENE; SVEP1 GENE; TIMP3 GENE; TP53 GENE; TPM1 GENE; TREATMENT RESPONSE;

ADULT; AGED; COMPARATIVE GENOMIC HYBRIDIZATION; COMPUTATIONAL BIOLOGY; DNA COPY NUMBER VARIATIONS; DNA METHYLATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84904246388     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0186     Document Type: Article

References (53)

1. ACS. Cancer facts and figures 2012. Atlanta: American Cancer Society; 2012.
2. Barnholtz-Sloan JS, Schwartz AG, Qureshi F, Jacques S, Malone J, Munkarah AR. Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol 2003;189:1120-7. (Pubitemid 37373908)
3. Friedlander ML, Stockler MR, Butow P, King MT, McAlpine J, Tinker A, et al. Clinical trials of palliative chemotherapy in platinum-resistant or -refractory ovarian cancer: time to think differently? J Clin Oncol 2013;31:2362.
4. Baker VV. Salvage therapy for recurrent epithelial ovarian cancer. Hematol Oncol Clin North Am 2003;17:977-88. (Pubitemid 37022153)
5. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, Anderson ME. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A 1992;89:3070-4.
6. Johnson SW, Laub PB, Beesley JS, Ozols RF, Hamilton TC. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res 1997;57:850-6. (Pubitemid 27098008)
7. Johnson SW, Swiggard PA, Handel LM, Brennan JM, Godwin AK, Ozols RF, et al. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells. Cancer Res 1994;54:5911-6. (Pubitemid 24375227)
8. Colombo PE, Fabbro M, Theillet C, Bibeau F, Rouanet P, Ray-Coquard I. Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer. Crit Rev Oncol Hematol 2013;89:207-16.
9. Hiss D. Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways. J Oncol 2012;2012:737981.
10. Zgheib NB, Xiong Y, Marchion DC, Bicaku E, Chon HS, Stickles XB, et al. The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer. Int J Oncol 2012;41:179- 88.
11. Bicaku E, Xiong Y, Marchion DC, Chon HS, Stickles XB, Chen N, et al. In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival. Br J Cancer 2012;106:1967-75.
12. Marchion DC, Cottrill HM, Xiong Y, Chen N, Bicaku E, Fulp WJ, et al. BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. Clin Cancer Res 2011;17:6356-66.
13. Bansal N, Marchion DC, Bicaku E, Xiong Y, Chen N, Stickles XB, et al. BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin. J Gynecol Oncol 2012;23:35-42.
14. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-7. (Pubitemid 43128862)
15. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008;14:5198-208.
16. Trinh XB, Tjalma WA, Dirix LY, Vermeulen PB, Peeters DJ, Bachvarov D, et al. Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma. PLoS ONE 2011;6:e22469.
17. Yoshihara K, Tajima A, Yahata T, Kodama S, Fujiwara H, Suzuki M, et al. Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets. PLoS ONE 2010;5:e9615.
18. Bonome T, Levine DA, Shih J, Randonovich M, Pise-Masison CA, Bogomolniy F, et al. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res 2008;68:5478-86.
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
20. Friedlander M, Butow P, Stockler M, Gainford C, Martyn J, Oza A, et al. Symptom control in patients with recurrent ovarian cancer: measuring the benefit ofpalliative chemotherapy inwomen with platinumrefractory/ resistant ovarian cancer. Int J Gynecol Cancer 2009;19 Suppl 2:S44-8.
21. Olshen AB, Venkatraman ES, Lucito R, Wigler M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 2004;5:557-72. (Pubitemid 41180205)
22. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A 2007;104:20007-12.
23. Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
24. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 2003;100:9440-5. (Pubitemid 37033947)
25. Wingender E, Chen X, Hehl R, Karas H, Liebich I, Matys V, et al. TRANSFAC: an integrated system for gene expression regulation. Nucleic Acids Res 2000;28:316-9. (Pubitemid 30047792)
26. Maurano MT, Wang H, Kutyavin T, Stamatoyannopoulos JA. Widespread site-dependent buffering of human regulatory polymorphism. PLoS Genet 2012;8:e1002599.
27. Moyer BD, Allan BB, Balch WE. Rab1 interaction with a GM130 effector complex regulates COPII vesicle cis-Golgi tethering. Traffic 2001;2:268-76. (Pubitemid 32487557)
28. Zahraoui A, Touchot N, Chardin P, Tavitian A. The human Rab genes encode a family of GTP-binding proteins related to yeast YPT1 and SEC4 products involved in secretion. J Biol Chem 1989;264:12394-401. (Pubitemid 19191130)
29. Ben-Hamo R, Efroni S. Biomarker robustness reveals the PDGF network as driving disease outcome in ovarian cancer patients in multiple studies. BMC Syst Biol 2012;6:3.
30. Bulavin DV, Higashimoto Y, Popoff IJ, Gaarde WA, Basrur V, Potapova O, et al. Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase. Nature 2001;411:102-7. (Pubitemid 32428198)
31. Wingender E. The TRANSFAC project as an example of framework technology that supports the analysis of genomic regulation. Brief Bioinform 2008;9:326-32. (Pubitemid 351894493)
32. Wingender E, Chen X, Fricke E, Geffers R, Hehl R, Liebich I, et al. The TRANSFAC system on gene expression regulation. Nucleic Acids Res 2001;29:281-3.
33. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature 2013;502:333-9.
34. Peifer M, Fernandez-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012;44:1104-10.
35. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012;486:400-4.
36. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999;21:163-7. (Pubitemid 29070360)
37. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics 2012;16:284-7.
38. Spriggs DR. Drug development for chronic cancers: time to think differently? J Clin Oncol 2012;30:3779-80.
39. Dutta S, Wang FQ, Phalen A, Fishman DA. Biomarkers for ovarian cancer detection and therapy. Cancer Biol Ther 2010;9:668-77.
40. Helleman J, Smid M, Jansen MP, van der Burg ME, Berns EM. Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture. Gynecol Oncol 2010;117:170-6.
41. Gevaert O, Villalobos V, Sikic BI, Plevritis SK. Identification of ovarian cancer driver genes by using module network integration of multiomics data. Interface Focus 2013;3:20130013.
42. Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ, et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest 2013;123:517-25.
43. Zhang W, Liu Y, Sun N, Wang D, Boyd-Kirkup J, Dou X, et al. Integrating genomic, epigenomic, and transcriptomic features reveals modular signatures underlying poor prognosis in ovarian cancer. Cell Rep 2013;4:542-53.
44. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
45. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005;4:307-20. (Pubitemid 41130944)
46. Qu J, Li X, Novitch BG, Zheng Y, Kohn M, Xie JM, et al. PAK4 kinase is essential for embryonic viability and for proper neuronal development. Mol Cell Biol 2003;23:7122-33. (Pubitemid 37210995)
47. Trahey M, Wong G, Halenbeck R, Rubinfeld B, Martin GA, Ladner M, et al. Molecular cloning of two types of GAP complementary DNA from human placenta. Science 1988;242:1697-700. (Pubitemid 19022176)
48. Yang SH, Sharrocks AD, Whitmarsh AJ. Transcriptional regulation by the MAP kinase signaling cascades. Gene 2003;320:3-21. (Pubitemid 37352751)
49. Aono N, Sutani T, Tomonaga T, Mochida S, Yanagida M. Cnd2 has dual roles in mitotic condensation and interphase. Nature 2002;417:197-202. (Pubitemid 34506802)
50. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010;376:245-51.
51. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365:2473-83.
52. Tortora G, Ciardiello F, Gasparini G. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. Nat Clin Pract Oncol 2008;5:521-30.
53. Pestell KE, Hobbs SM, Titley JC, Kelland LR, Walton MI. Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line. Mol Pharmacol 2000;57:503-11.